Guardant Health (NASDAQ:GH) Insider Sells $865,865.00 in Stock

Guardant Health, Inc. (NASDAQ:GH) insider John Saia sold 8,996 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $96.25, for a total transaction of $865,865.00. Following the transaction, the insider owned 43,172 shares of the company’s stock, valued at approximately $4,155,305. This represents a 17.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Guardant Health Stock Performance

Shares of GH stock traded up $1.20 during trading hours on Monday, hitting $97.92. The company had a trading volume of 2,825,243 shares, compared to its average volume of 2,477,553. Guardant Health, Inc. has a 12 month low of $28.45 and a 12 month high of $101.57. The firm’s fifty day moving average is $67.52 and its 200 day moving average is $55.11. The firm has a market capitalization of $12.34 billion, a price-to-earnings ratio of -30.50 and a beta of 1.56.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.26). The company had revenue of $265.20 million during the quarter, compared to analyst estimates of $235.72 million. During the same quarter last year, the company posted ($0.88) earnings per share. Guardant Health’s quarterly revenue was up 38.5% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analyst Ratings Changes

GH has been the subject of a number of recent analyst reports. Wolfe Research upgraded shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price for the company in a research report on Thursday, September 25th. Canaccord Genuity Group set a $100.00 price objective on shares of Guardant Health in a research note on Thursday, October 30th. Mizuho set a $100.00 target price on shares of Guardant Health in a research note on Thursday, October 30th. Guggenheim increased their price target on Guardant Health from $56.00 to $67.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, JPMorgan Chase & Co. lifted their price objective on Guardant Health from $60.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.14.

Institutional Trading of Guardant Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC grew its stake in shares of Guardant Health by 37.3% during the first quarter. Intech Investment Management LLC now owns 60,187 shares of the company’s stock worth $2,564,000 after purchasing an additional 16,363 shares during the period. Teacher Retirement System of Texas bought a new position in Guardant Health during the first quarter worth about $866,000. Osterweis Capital Management Inc. bought a new stake in shares of Guardant Health in the 1st quarter valued at about $12,634,000. Yorktown Management & Research Co Inc acquired a new stake in shares of Guardant Health in the 2nd quarter valued at approximately $289,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Guardant Health by 6.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,236 shares of the company’s stock valued at $3,035,000 after acquiring an additional 4,056 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.